| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2021-09-07 16:45:29 UTC |
|---|
| HMDB ID | HMDB0001238 |
|---|
| Secondary Accession Numbers | - HMDB0061066
- HMDB01238
- HMDB61066
|
|---|
| Metabolite Identification |
|---|
| Common Name | N-Acetylserotonin |
|---|
| Description | N-Acetylserotonin (NAS), also known as normelatonin, is a naturally occurring chemical precursor and intermediate in the endogenous production of melatonin from serotonin. It also has biological activity in its own right, including acting as a melatonin receptor agonist, an agonist of the TrkB, and having antioxidant effects. N-Acetylserotonin is an intermediate in the metabolic pathway of melatonin and indoleamine in the pineal gland of mammalians. Serotonin-N-acetyltransferase (SNAT), which regulates the rate of melatonin biosynthesis in the pineal gland, catalyzes the acetylation of 5HT to N-acetylserotonin (NAS). A methyl group from S-adenosylmethionine is transferred to NAS by hydroxyindole-O-methyltransferase (HIOMT), and finally NAS is converted to 5-methoxy-N-acetyltryptamine, or melatonin. In most mammalian species the content of NAS (and melatonin) in the pineal gland shows clear circadian changes with the highest level occurring during the dark period. This elevation of the contents of NAS (and melatonin) in the dark period is due to the increase of SNAT activity and the elevation of SNAT gene expression. Experimental studies show that N-acetylserotonin possess free radical scavenging activity. Acute administration of irreversible and reversible selective MAO-A inhibitors and high doses (or chronic administration of low doses) of relatively selective MAO-B inhibitors (but not of highly selective MAO-B inhibitors) suppressed MAO-A activity and stimulated N-acetylation of pineal serotonin into N-acetylserotonin, the immediate precursor of melatonin. N-acetylserotonin increase after MAO-A inhibitors might mediate their antidepressive and antihypertensive effects. N-Acetylserotonin is the product of the O-demethylation of melatonin mediated by cytochrome P-450 isoforms: Cytochrome p450, subfamily IIc, polypeptide 19 (CYP2C19, a clinically important enzyme that metabolizes a wide variety of drugs), with a minor contribution from Cytochrome p450, subfamily I, polypeptide (2CYP1A2, involved in O-deethylation of phenacetin). (PMID 15616152 , 11103901 , 10721079 , 10591054 ). N-Acetylserotonin acts as a potent antioxidant, NAS effectiveness as an anti-oxidant has been found to be different depending on the experimental model used, it has been described as being between 5 and 20 times more effect than melatonin at protecting against oxidant damage. NAS has been shown to protect against lipid peroxidation in microsomes and mitochondria. NAS has also been reported to lower resting levels of ROS in peripheral blood lymphocytes and to exhibit anti-oxidant effects against t-butylated hydroperoxide- and diamide-induced ROS. |
|---|
| Structure | CC(=O)NCCC1=CNC2=C1C=C(O)C=C2 InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15) |
|---|
| Synonyms | | Value | Source |
|---|
| N-(2-(5-Hydroxy-1H-indol-3-yl)ethyl)acetamide | ChEBI | | N-Acetyl-5-hydroxytryptamine | ChEBI | | 5-Hydroxy-N-acetyltryptamine | HMDB | | 5-Hydroxymelatonin | HMDB | | ASE | HMDB | | Desmethylmelatonin | HMDB | | O-Demethylmelatonin | HMDB | | N-Acetylhydroxytryptamine | HMDB |
|
|---|
| Chemical Formula | C12H14N2O2 |
|---|
| Average Molecular Weight | 218.2518 |
|---|
| Monoisotopic Molecular Weight | 218.105527702 |
|---|
| IUPAC Name | N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide |
|---|
| Traditional Name | N-acetylserotonin |
|---|
| CAS Registry Number | 1210-83-9 |
|---|
| SMILES | CC(=O)NCCC1=CNC2=C1C=C(O)C=C2 |
|---|
| InChI Identifier | InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15) |
|---|
| InChI Key | MVAWJSIDNICKHF-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as hydroxyindoles. These are organic compounds containing an indole moiety that carries a hydroxyl group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Indoles and derivatives |
|---|
| Sub Class | Hydroxyindoles |
|---|
| Direct Parent | Hydroxyindoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - Hydroxyindole
- 3-alkylindole
- Indole
- 1-hydroxy-2-unsubstituted benzenoid
- Substituted pyrrole
- Benzenoid
- Pyrrole
- Heteroaromatic compound
- Carboximidic acid
- Carboximidic acid derivative
- Azacycle
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Organic oxygen compound
- Organooxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.89 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.8272 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.07 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 26.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1344.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 266.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 105.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 153.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 157.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 326.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 278.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 110.4 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 652.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 307.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1125.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 276.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 225.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 419.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 221.8 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 103.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| N-Acetylserotonin,1TMS,isomer #1 | CC(=O)NCCC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12 | 2464.3 | Semi standard non polar | 33892256 | | N-Acetylserotonin,1TMS,isomer #2 | CC(=O)N(CCC1=C[NH]C2=CC=C(O)C=C12)[Si](C)(C)C | 2409.8 | Semi standard non polar | 33892256 | | N-Acetylserotonin,1TMS,isomer #3 | CC(=O)NCCC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12 | 2460.8 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #1 | CC(=O)N(CCC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)[Si](C)(C)C | 2382.2 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #1 | CC(=O)N(CCC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)[Si](C)(C)C | 2546.1 | Standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #1 | CC(=O)N(CCC1=C[NH]C2=CC=C(O[Si](C)(C)C)C=C12)[Si](C)(C)C | 2673.7 | Standard polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #2 | CC(=O)NCCC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12 | 2477.2 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #2 | CC(=O)NCCC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12 | 2408.7 | Standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #2 | CC(=O)NCCC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12 | 2680.6 | Standard polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #3 | CC(=O)N(CCC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)[Si](C)(C)C | 2437.6 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #3 | CC(=O)N(CCC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)[Si](C)(C)C | 2638.8 | Standard non polar | 33892256 | | N-Acetylserotonin,2TMS,isomer #3 | CC(=O)N(CCC1=CN([Si](C)(C)C)C2=CC=C(O)C=C12)[Si](C)(C)C | 2704.3 | Standard polar | 33892256 | | N-Acetylserotonin,3TMS,isomer #1 | CC(=O)N(CCC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)[Si](C)(C)C | 2437.7 | Semi standard non polar | 33892256 | | N-Acetylserotonin,3TMS,isomer #1 | CC(=O)N(CCC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)[Si](C)(C)C | 2546.0 | Standard non polar | 33892256 | | N-Acetylserotonin,3TMS,isomer #1 | CC(=O)N(CCC1=CN([Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C12)[Si](C)(C)C | 2516.0 | Standard polar | 33892256 | | N-Acetylserotonin,1TBDMS,isomer #1 | CC(=O)NCCC1=C[NH]C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 | 2739.4 | Semi standard non polar | 33892256 | | N-Acetylserotonin,1TBDMS,isomer #2 | CC(=O)N(CCC1=C[NH]C2=CC=C(O)C=C12)[Si](C)(C)C(C)(C)C | 2653.9 | Semi standard non polar | 33892256 | | N-Acetylserotonin,1TBDMS,isomer #3 | CC(=O)NCCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C12 | 2713.7 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #1 | CC(=O)N(CCC1=C[NH]C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12)[Si](C)(C)C(C)(C)C | 2877.9 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #1 | CC(=O)N(CCC1=C[NH]C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12)[Si](C)(C)C(C)(C)C | 2973.6 | Standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #1 | CC(=O)N(CCC1=C[NH]C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12)[Si](C)(C)C(C)(C)C | 2848.1 | Standard polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #2 | CC(=O)NCCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 | 2975.2 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #2 | CC(=O)NCCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 | 2851.8 | Standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #2 | CC(=O)NCCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12 | 2829.7 | Standard polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #3 | CC(=O)N(CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C12)[Si](C)(C)C(C)(C)C | 2876.5 | Semi standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #3 | CC(=O)N(CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C12)[Si](C)(C)C(C)(C)C | 3030.6 | Standard non polar | 33892256 | | N-Acetylserotonin,2TBDMS,isomer #3 | CC(=O)N(CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C12)[Si](C)(C)C(C)(C)C | 2832.5 | Standard polar | 33892256 | | N-Acetylserotonin,3TBDMS,isomer #1 | CC(=O)N(CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12)[Si](C)(C)C(C)(C)C | 3097.3 | Semi standard non polar | 33892256 | | N-Acetylserotonin,3TBDMS,isomer #1 | CC(=O)N(CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12)[Si](C)(C)C(C)(C)C | 3146.0 | Standard non polar | 33892256 | | N-Acetylserotonin,3TBDMS,isomer #1 | CC(=O)N(CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C12)[Si](C)(C)C(C)(C)C | 2809.5 | Standard polar | 33892256 |
|
|---|
| Disease References | | Schizophrenia |
|---|
- Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33. Epub 2009 Apr 28. [PubMed:19401681 ]
|
|
|---|
| General References | - Ma X, Idle JR, Krausz KW, Gonzalez FJ: Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94. Epub 2004 Dec 22. [PubMed:15616152 ]
- Harumi T, Matsushima S: Separation and assay methods for melatonin and its precursors. J Chromatogr B Biomed Sci Appl. 2000 Sep 29;747(1-2):95-110. [PubMed:11103901 ]
- Reiter RJ, Tan DX, Cabrera J, D'Arpa D: Melatonin and tryptophan derivatives as free radical scavengers and antioxidants. Adv Exp Med Biol. 1999;467:379-87. [PubMed:10721079 ]
- Oxenkrug GF: Antidepressive and antihypertensive effects of MAO-A inhibition: role of N-acetylserotonin. A review. Neurobiology (Bp). 1999;7(2):213-24. [PubMed:10591054 ]
- Brunk E, Sahoo S, Zielinski DC, Altunkaya A, Drager A, Mih N, Gatto F, Nilsson A, Preciat Gonzalez GA, Aurich MK, Prlic A, Sastry A, Danielsdottir AD, Heinken A, Noronha A, Rose PW, Burley SK, Fleming RMT, Nielsen J, Thiele I, Palsson BO: Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat Biotechnol. 2018 Mar;36(3):272-281. doi: 10.1038/nbt.4072. Epub 2018 Feb 19. [PubMed:29457794 ]
|
|---|